The earnings call presented a mixed outlook. While the clinical segment showed robust growth and operational achievements, significant challenges in the nonclinical and pharma segments led to a downward revision of the full-year financial guidance. The company is taking steps to address these issues, but the immediate future appears cautious.

Company Guidance

During the NeoGenomics Second Quarter 2025 Financial Results Call, the company provided updated financial guidance, projecting full-year revenue of $720 million to $726 million, reflecting 9% to 10% growth. This adjustment accounts for a $30 million reduction in guidance, with approximately two-thirds attributed to challenges in the pharma segment due to market uncertainties affecting NIH funding, drug pricing, and clinical trial enrollments. The clinical business demonstrated strong performance, with a 16% year-over-year growth, driven by a 10% increase in test volumes and a 3% increase in average unit price (AUP). Notably, next-generation sequencing (NGS) testing grew by 23%, accounting for 32% of total clinical revenue, although slightly below the 25% target. The delay in the launch of the PanTracer liquid biopsy contributed to lower-than-expected NGS growth, but the product is set for commercial launch imminently. The company remains focused on strategic investments in its sales force, digital pathology, and LIMS integration to enhance operational efficiencies and drive future growth.

Solid Clinical Revenue Growth

Clinical revenue grew by 16% year-over-year, with organic clinical revenue increasing by 13%, driven by a 10% increase in test volumes and a 3% increase in AUP.

NGS Testing Expansion

NGS testing accounted for 32% of total clinical revenue and grew by 23% over the prior year, demonstrating strong market expansion.

Record High Test Volumes

The company reported a record quarter for test volumes, indicating robust demand and operational capacity.

Launch of PanTracer Liquid Biopsy

The PanTracer liquid biopsy is set to launch, expected to positively impact the NGS growth rate later in the year.

Cash Flow and Debt Reduction

Cash flow from operations was a positive $20 million, an improvement of 44% over the prior year, and the company significantly reduced debt by retiring $201 million in convertible notes.

NeoGenomics (NEO) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

NEO Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 11, 2025	2025 (Q3)	0.02 / -	0.05	―	―	―
Jul 29, 2025	2025 (Q2)	0.02 / 0.03	0.03	0.00% (0.00)
Apr 29, 2025	2025 (Q1)	-0.01 / 0.00	-0.02	―
Feb 18, 2025	2024 (Q4)	0.03 / 0.04	0.03	33.33% (+0.01)
Nov 05, 2024	2024 (Q3)	0.01 / 0.05	0	―
Jul 29, 2024	2024 (Q2)	>-0.01 / 0.03	-0.05	160.00% (+0.08)
Apr 30, 2024	2024 (Q1)	-0.04 / -0.02	-0.09	77.78% (+0.07)
Feb 20, 2024	2023 (Q4)	-0.03 / 0.03	-0.06	150.00% (+0.09)
Nov 06, 2023	2023 (Q3)	-0.07 / 0.00	-0.14	―
Aug 08, 2023	2023 (Q2)	-0.11 / -0.05	-0.16	68.75% (+0.11)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

NEO Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Jul 29, 2025	$6.46	$5.25	-18.73%
Apr 29, 2025	$9.97	$6.58	-34.00%
Feb 18, 2025	$14.42	$12.40	-14.01%
Nov 05, 2024	$14.14	$14.93	+5.59%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.